Granulocyte-macrophage colony-stimulating factor (GM-CSF) production and receptor expression by human glioblastomas was studied. Enzyme-linked immunosorbent assay showed four of 10 glioblas toma cell lines spontaneously released GM-CSF (2.9-9.2 pg GM-CSF protein/ml culture medium), which was enhanced by stimulation with tumor necrosis factor-&alpha; (TNF) (10 U&frasl;ml) up to 410 pg&frasl; ml. TNF also induced secretion of GM-CSF by another cell line. Northern blot analysis identified in creasing GM-CSF gene expression by cells following TNF stimulation. However, no GM-CSF protein was detectable in the cerebrospinal fluid of three malignant glioma patients. Intratumoral ad ministration of TNF in the patients also failed to stimulate GM-CSF levels in the cerebrospinal fluid. A binding assay using flow cytometry with biotinylated GM-CSF and Scatchard analysis using <SUP>125</SUP>I-label ed GM-CSF failed to demonstrate GM-CSF receptor expression on the 13 cell lines. Exogenous GM-CSF stimulation had no effect on production of prostaglandin E<SUB>2</SUB>, interleukin-6, or interleukin-8 by glioma cells. Human glioblastoma cells secrete GM-CSF without expressing the receptor <I>in vitro</I>, but there was no evidence of GM-CSF production <I>in vivo</I>.
Introduction
Granulocyte-macrophage colony-stimulating factor (GM-CSF), produced by T-lymphocytes, monocytes, fibroblasts, endothelial cells, and epithelial cells, in duces the proliferation and maturation of hematopoietic progenitor cells to produce colonies of granulocytes, macrophages, and monocytes." These GM-CSF-producing cells do not normally syn thesize GM-CSF, but release GM-CSF in response to an activation stimulus. GM-CSF production by en dothelial cells, fibroblasts, and several tumor cells is induced by tumor necrosis factor-(x (TNF).16) Glial origin cells including murine astrocytes and human glioma cell lines produce GM-CSF in vitro. 8, 14, 24, 25) GM-CSF targets other cells beside hematopoietic cells. In the rodent central nervous system, GM-CSF induces both morphological changes and prolifera tion of microglia, and activates the phagocytic behavior. 1,21) GM-CSF also acts on nonhematopoi etic human tumor cells, including small-cell lung cancer (SCLC),'"18) osteosarcoma,7) breast cancer,') colon cancer, 2) non-SCLC,15) and stomach cancer.'5 The presence of GM-CSF receptor on glioma cells, however, has not been clarified. The possibility that glioblastoma cells express GM-CSF receptors is of great clinical interest, because GM-CSF may then affect tumor growth.
Glioblastoma IV. Northern blot analysis Four glioblastoma cell lines were cultured at 37°C in the presence (100 U/ml) or absence of TNF for 4 hours. The cells were then lysed and homoge nized in guanidine thiocyanate solution. Poly(A)+ ribonucleic acid (RNA) was isolated using an oligo (dT)-cellulose spun column (Pharmacia LKB Bio tech., Upsala, Sweden).
1,ug of poly(A)+RNA was fractionated by size using electrophoresis through a 1.5% agarose for maldehyde gel and transferred onto a nylon mem brane (Schleicher & Schull, Dassel, Germany) in 10 x standard saline citrate (SSC). 0.7 kb GM-CSF complementary deoxyribonucleic acid (DNA), a generous gift from Dr. M. Kobayashi (Hokkaido University, Sapporo), was labeled with [a32P]deox ycytidine triphosphate using a random primer DNA labeling kit (Takara Biomedicals, Kyoto). After pre hybridization, the blots were hybridized with the probes in the buffer containing 0.5 x Denhardt's re agent, 1 % sodium dodecyl sulfate (SDS), 50% form amide, and single-stranded salmon sperm DNA (50 ,ug/ml) at 43'C overnight. The blots were finally washed with 0.1 x SSC, 0.1 % SDS at 65 °C, and exposed to X-Omat AR film (Kodak, Rochester, N.Y., U.S.A.) at -80'C for 72 hours.
V. Flow cytometry GM-CSF binding of 13 cell lines was assessed using a Fluorokine GM-CSF Kit (R & D Systems, Minneapolis, Minn., U.S.A.). Briefly, glioblastoma cells were detached with 0.5 mM ethylenediamine tetra-acetic acid and harvested. Peripheral blood monocytes (PBM) and TF-1 cells were used as posi tive controls for GM-CSF binding. TF-1 cells were harvested after 48-hour incubation in the GM-CSF free medium. Each cell suspension of 4 x 106 cells/ ml was incubated for 1 hour at 4°C with biotinyl ated rhGM-CSF or phosphate buffered saline con taining 0.2% bovine serum albumin as a control. .9 x 103-7.9 x 105 cpm) of 125I-labeled rhGM CSF were incubated for 2 hours at 4°C with or without a 100-fold molar excess of unlabeled GM CSF for cold inhibition. Samples were then layered onto a small volume of silicone oil in a tube. Follow ing centrifugation, the bound (cell pellet) and free (supernatant) radioactivity was counted. True bound activity was determined by subtracting the cold-inhibited bound activity. Assays were done in triplicate.
VII.
Radioimmunoassay for PGE2 The assay used the PGE2['211] assay system (Amer sham, Buckinghamshire, U.K.). Briefly, the cells of nine cell lines were incubated for 24 hours in the presence (5 ng/ml) or absence of rhGM-CSF. PGE2 released in the culture medium competed with 1251_ labeled PGE2 for a PGE2 specific antibody. The radioactivity of labeled ligand bound by the an tibody was measured, where the concentration was inversely proportional to that of unlabeled ligand. The concentration of unlabeled ligand was then deter mined by interpolation from a standard curve. Assays were done in triplicate.
VIII.
Bioassay for IL-6 and IL-8 Approximately 5 x 104 cells of 13 cell lines were incubated for 24 hours in the presence (5 or 50 ng/ ml) or absence of rhGM-CSF. IL-6 released in the culture medium was measured using a Quantikine Human IL-6 Immunoassay Kit (R & D Systems). Samples were incubated in the wells coated by anti IL-6 monoclonal antibody for 2 hours, then with an enzyme-linked anti-IL-6 polyclonal antibody for another 2 hours. Color reagents were added and the concentration of IL-6 was determined by comparing the optical density with the standard samples. IL-8 was measured using Quantikine Human IL-8 Im munoassay Kit (R & D Systems). The procedure was identical to that for the IL-6 assay. (open bars) of TNF 10 U/ml for 24 hours. GM-CSF level was determined using an ELISA kit. The minimum detection limit of the assay was 2 pg/ml (dotted line).
Results

I.
GM-CSF production by glioblastoma cells in vitro Four glioblastoma cell lines, LN-382, SF-126, HUG-1, and U-251 MG, spontaneously produced GM-CSF, 5.8, 9.2, 2.9, and 2.9 pg GM-CSF protein/ ml culture medium, respectively. After exposure to 10 U/ml TNF for 24 hours, production increased up to 410, 86, 25, and 26 pg/ml, respectively. LN-235 was induced to secrete 22 pg/ml GM-CSF by TNF stimulation (Fig. 1) . Higher doses or longer ex posures of TNF did not cause further increases in GM-CSF production in these five cell lines (data not shown). The other five cell lines did not release GM CSF, even when exposed to TNF.
Northern blot analysis identified GM-CSF specific messenger RNA (mRNA), a signal of approximately 0.7 kb, in three cell lines including LN-235, LN-382, and SF-126. When stimulated by TNF (100 U/ml), the signal was enhanced remarkably in these three lines, but not in SF-188 (Fig. 2) .
II. GM-CSF and IL-6 production, in vivo
All cerebrospinal fluid samples obtained from three patients contained no measurable GM-CSF before and after TNF administration (Table 1) . IL-6 levels in the fluid were 3.8, < 0.5, and 4.0 U/ml in Cases 1, 2, and 3, respectively. After TNF injection, IL-6 levels rose to 72.5, 35.7, and 62.5 U/ml, respec tively. biotinylated rhGM-CSF (data not shown). Cold in hibition with a 100-fold molar excess of non biotinylated rhGM-CSF was therefore examined with these four cell lines. The population curves of the two lines, LN-319 and SF-188, were slightly shifted toward lower FITC fluorescence by cold in hibition (Fig. 3) .
Scatchard analysis was also performed on cell lines LN-319 and SF-188. The bound radioactivity was, however, almost equal to the nonspecific bound ac tivity evaluated by cold inhibition in both cell lines (data not shown). Therefore, no true bound activity was found.
IV.
Effect of exogenous GM-CSF on secretion of PGE2, IL-6, and IL-8 by glioblastoma cells
Four of the nine cell lines spontaneously produced PGE2 at a few ng/ml at most. 5 ng/ml of rhGM-CSF caused no significant increase in PGE2 release in these four cell lines and induced no GM-CSF produc tion in the other five lines (Table 2) . Four of 13 cell lines spontaneously produced several ng/ml of IL-6, but no significant increase was seen after stimulation with rhGM-CSF. rhGM-CSF did not induce IL-6 release in the other nine cell lines (Table 3) .
Nine of 13 cell lines spontaneously produced more than 1 ng/ml of IL-8, however, IL-8 levels were not significantly increased even when exposed to a high concentration of rhGM-CSF. The other four cell lines showed no induction of IL-8 release when ex posed to rhGM-CSF (Table 4) . Table 2 PGE2 secretion (ng/ml) by glioblastoma cells Table 3 IL-6 secretion (ng/ml) by glioblastoma cells Table 4 IL-8 secretion (ng/ml) by glioblastoma cells
Discussion
Human glioblastoma cell production of GM-CSF was analyzed both in vitro and in vivo. Four of 10 cell lines spontaneously produced a small amount of GM-CSF, which was enhanced by TNF stimulation. TNF induced another line to secrete GM-CSF. The mRNA coding for GM-CSF was also identified by Northern blot analysis, and GM-CSF gene expres sion enhanced by TNF stimulation.
Tweardy et al.") first showed that human astroglial cell lines produce GM-CSF, and IL-la or IL-1/3 causes enhancement. Frei et al.') demonstrated that five glioblastoma cell lines produced GM-CSF only when stimulated with TNF, IL-la, or IL-1/3. However, the detection limit of GM-CSF protein was more than 30 pg/ml. Our study showed that spontaneous GM-CSF production was approximate ly less than 10 pg GM-CSF protein/ml culture medium.
Our study detected no GM-CSF in the cerebrospinal fluid of patients. Frei et al.') detected no GM-CSF in vivo including fresh tumor samples, tumor cyst fluid, and cerebrospinal fluid. They speculated that possible tumor-derived inhibitory fac tors in vivo, such as transforming growth factor (TGF)-/32 and PGE2, suppress GM-CSF production by glioblastoma cells in vitro. TGF-/32 and PGE2 are secreted by human glioblastomas in vivo.3'4) We studied the effect of TNF on GM-CSF production in vivo by treating glioma patients with TNF in a phase I clinical trial. The cerebrospinal fluid contained no detectable GM-CSF after intracranial TNF ad ministration, while the IL-6 level increased remarkably after TNF injection.
We also investigated GM-CSF receptor expression by glioblastoma cells. The GM-CSF receptor protein contains a and$ subunits of 80 and 135 kDa, respec tively. 5,20) The a subunit binds GM-CSF with low affinity. 
